Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Array BioPharma and Genentech enter agreement for Chk1 program

Aug. 11, 2011

New histone deacetylase 9 inhibitors claimed

Aug. 11, 2011

Novel B-raf inhibitors patented by Selexagen

Aug. 11, 2011

New radioimmunotherapy enters phase I evaluation in HER2-positive intra-abdominal cancers

Aug. 10, 2011

DelMar Pharmaceuticals receives Canada Industrial Research Assistance Program funding

Aug. 10, 2011

U.S. Department of Defense contracts Neuralstem to develop brain tumor therapy

Aug. 10, 2011

Tempero Pharmaceuticals presents novel histone deacetylase 9 inhibitors

Aug. 10, 2011

RNAi screen leads to identification of new target and agent for treatment of AML

Aug. 9, 2011

Phase III study of tivantinib/erlotinib combination begins in NSCLC

Aug. 9, 2011

ESMO and Thomson Reuters launch OncologyPRO portal

Aug. 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.